Second Annual FDA ASCO WORKSHOP
Optimizing Dosage Selection Strategies in Combination Cancer Therapies.
Optimizing Dosage Selection Strategies in Combination Cancer Therapies.
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
Agencje rejestrujące leki, takie jak FDA czy EMA, mogą dopuszczać leki w procedurze przyspieszonej lub warunkowo. Bywa, że jeśli lek okaże się nieskuteczny, może zostać…
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Promoting collaboration in design and analysis of cancer clinical trials
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Assisting Healthcare Providers with Expanded Access Requests for Investigational Oncology Products
A monthly newsletter for oncology/hematology fellows, junior faculty and scientists
On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) fo
On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) fo